Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 18/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 18/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 18/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.66 |
| ▸ | VNN1 | O95497 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16644383 | 0.94 | HDAC3 (0.76) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL16644382 | 0.93 | HDAC3 (0.70) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL16644356 | 0.91 | HDAC3 (0.71) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL17832599 | 0.90 | HDAC1 (0.62) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL16626820 | 0.90 | VNN1 (0.64) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL16632314 | 0.90 | HDAC3 (0.82) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL16644348 | 0.89 | HDAC3 (0.71) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL16644404 | 0.88 | HDAC3 (0.69) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL18742411 | 0.88 | HDAC3 (0.65) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL18742534 | 0.88 | HDAC3 (0.65) | HDAC3HDAC1HDAC2HDAC6VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160279128-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-9278963-B2 | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors | ACETYLON PHARMACEUTICALS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150105384-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| WO-2015054474-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279128-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | HDAC3 11/4885HDAC1 1/4885HDAC2 3/4885 |
| US-20150105384-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | HDAC3 11/4885HDAC1 1/4885HDAC2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.